Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients. Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software …
We’re happy to announce that we’ve received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program (MDSAP)! The MDSAP is a stringent audit process that allows for a recognized auditing organization to conduct a single regulatory audit of a medical device manufacturer that, in addition to …
New methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection of relapse and initiation of treatment to improve and save the lives of transplanted patients. Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, shares why Karolinska decided to replace their STR-PCR and qPCR methods with a …
Case Study – A new NGS-based method for chimerism monitoring Read More »
IMSS, Mexico’s largest public health care provider and INP, Mexico’s National Institute of Pediatrics, now use Devyser’s solutions for chimerism monitoring of transplanted patients Stockholm 13 October 2020 – Devyser’s solutions are implemented in routine testing at Mexico’s largest public health care provider, IMSS, and Mexico’s National Institute of Pediatrics, INP. Both centers will be …
We’re shipping! While the world focused on Covid-19 testing, cancer did not take a break. We’re so relieved that priorities are now diversifying to include important routine testing for cancer and other hereditary diseases. Patients all over the world will be able to receive diagnosis and begin treatment. On the shipping table today are also …
Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to 18th 2020. Visit our virtual booth to learn more about our upcoming solution for the non-invasive detection of fetal RHD status as well as Devyser Chimerism, our chimerism monitoring solution. …
Devyser welcomes Fredrik Alpsten as new CEO starting September 1st. Ulf Klangby, the former CEO and founder of Devyser, continues as COO and board member of Devyser. Fredrik Alpsten has more than 25 years of experience from executive positions within the life science industry, mainly at listed companies. His experience includes six years as Group …
https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated with Cystic Fibrosis. List of mutations detected by Devyser CFTR 68 711+ 1G>T, 2043delG, 1677delTA, W1282X, R1283M, K710X, 3849+10kbC>T, 2789+5G>A, M1101K, G85E, 3905insT, 1525-1G>A, 2184delA, 3659delC, N1303K, 2184insA, 1812-1G->A, CFTRdele2,3, …
The Q&A Poster viewing sessions at ESHG 2020 Virtual Conference will highlight two of our products: Devyser RHD, a non-invasive risk screening kit for RhD-negative mothers and Devyser Thalassemia, a single-tube NGS kit for Thalassemia detection. Devyser RHD Sunday, June 7th – 13.00 – 13.45 CEST P01.109.A: “A fast and non-invasive method for fetal RHD …
Join our Q&A Poster viewings at the ESHG 2020 Virtual Conference! Read More »
From June 1st to June 7th 2020 is World Haemochromatosis Week. Hemochromatosis is characterised by an excess of iron in blood. Causes for the disease are mostly hereditary and the illness can be diagnosed by genetic testing. Hemochromatosis is often overlooked because its symptoms are generally non-specific and can be confused with other illnesses. The …
